Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

NCT05661240 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

348

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DEVICE: Tumor treating fields（EFE-P100）
DRUG: Docetaxel injection

Sponsor

Jiangsu Healthy Life Innovation Medical Technology Co., Ltd